32.97
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SUPN Giù?
Forum
Previsione
Precedente Chiudi:
$32.67
Aprire:
$32.82
Volume 24 ore:
279.18K
Relative Volume:
0.49
Capitalizzazione di mercato:
$1.85B
Reddito:
$651.97M
Utile/perdita netta:
$59.71M
Rapporto P/E:
30.82
EPS:
1.0696
Flusso di cassa netto:
$172.03M
1 W Prestazione:
-1.64%
1M Prestazione:
+3.06%
6M Prestazione:
-14.67%
1 anno Prestazione:
+10.27%
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Nome
Supernus Pharmaceuticals Inc
Settore
Telefono
301-838-2500
Indirizzo
9715 KEY WEST AVENUE, ROCKVILLE, MD
Confronta SUPN con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
SUPN
Supernus Pharmaceuticals Inc
|
32.97 | 1.83B | 651.97M | 59.71M | 172.03M | 1.0696 |
![]()
ZTS
Zoetis Inc
|
153.45 | 67.31B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.74 | 45.95B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
HLN
Haleon Plc Adr
|
9.75 | 43.35B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.58 | 18.68B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
305.61 | 13.44B | 2.99B | 1.21B | 1.13B | 25.06 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-02-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
2025-01-06 | Iniziato | Cantor Fitzgerald | Overweight |
2024-09-11 | Downgrade | Piper Sandler | Overweight → Neutral |
2023-01-03 | Ripresa | Jefferies | Buy |
2021-12-01 | Ripresa | Jefferies | Buy |
2021-04-13 | Aggiornamento | Jefferies | Hold → Buy |
2020-06-16 | Aggiornamento | Piper Sandler | Neutral → Overweight |
2020-06-15 | Ripresa | Jefferies | Hold |
2019-11-08 | Downgrade | Berenberg | Buy → Hold |
2019-11-07 | Downgrade | Stifel | Buy → Hold |
2019-11-06 | Downgrade | Jefferies | Buy → Hold |
2018-11-12 | Reiterato | B. Riley FBR | Buy |
2018-01-18 | Reiterato | B. Riley FBR, Inc. | Buy |
2017-12-28 | Reiterato | B. Riley FBR, Inc. | Buy |
2017-12-04 | Aggiornamento | Janney | Neutral → Buy |
2017-11-08 | Aggiornamento | Stifel | Hold → Buy |
2017-10-19 | Iniziato | FBR & Co. | Buy |
2017-09-19 | Downgrade | Stifel | Buy → Hold |
2017-07-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
2017-07-14 | Iniziato | Janney | Neutral |
2017-06-01 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
2016-07-18 | Downgrade | Northland Capital | Outperform → Market Perform |
2016-07-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
2016-02-08 | Aggiornamento | Jefferies | Hold → Buy |
2015-11-05 | Reiterato | Northland Capital | Outperform |
2015-10-28 | Iniziato | Northland Capital | Outperform |
Mostra tutto
Supernus Pharmaceuticals Inc Borsa (SUPN) Ultime notizie
Is Supernus Pharmaceuticals Inc. a good long term investmentExtraordinary performance - Autocar Professional
Supernus Pharmaceuticals Inc. Stock Analysis and ForecastStrong return on investment - Autocar Professional
Benign Growth For Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Underpins Its Share Price - simplywall.st
Published on: 2025-07-23 12:28:32 - Autocar Professional
Supernus Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 5 - Quiver Quantitative
Supernus Pharmaceuticals to Announce Second Quarter 2025 - GlobeNewswire
Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025 - Yahoo.co
What analysts say about Supernus Pharmaceuticals Inc. stockTremendous portfolio expansion - jammulinksnews.com
What drives Supernus Pharmaceuticals Inc. stock priceExtraordinary performance - jammulinksnews.com
Supernus Pharmaceuticals Faces 3.2% Share Decline: Sector Challenges ImpactNews and Statistics - IndexBox
(SUPN) Investment Report - news.stocktradersdaily.com
Why Supernus Pharmaceuticals (SUPN) Shares Are Falling Today - Yahoo Finance
Is Supernus Pharmaceuticals Inc. stock a growth or value playQuick Profit Idea Stream - Newser
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Holdings Lowered by Teacher Retirement System of Texas - Defense World
Why Supernus Pharmaceuticals Inc. stock attracts strong analyst attentionTop Rated Trade Entries - Newser
How Supernus Pharmaceuticals Inc. stock performs during market volatilityStrong Buy Recommendations - Newser
What makes Supernus Pharmaceuticals Inc. stock price move sharplyFree Stock Market Expert Consultation - Newser
Principal Financial Group Inc. Boosts Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Amalgamated Bank - Defense World
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Allspring Global Investments Holdings LLC - Defense World
When the Price of (SUPN) Talks, People Listen - news.stocktradersdaily.com
Supernus Pharmaceuticals to Acquire Sage Therapeutics in Transaction Valued Up to $795 Million - Global Legal Chronicle
Busy Philipps, Jay Glazer highlight ADHD experiences in Supernus’ campaigns - Medical Marketing and Media
Supernus Pharmaceuticals’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 6.8% CAGR over the last five years - Yahoo Finance
Supernus to acquire Sage Therapeutics stock for $8.50 per share By Investing.com - Investing.com UK
Supernus to acquire depression drugmaker Sage - MSN
Apomorphine Delivery Device Market Set to Witness Significant - openPR.com
Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics - MSN
Supernus Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal - Yahoo Finance
These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News - Benzinga
Supernus buys Sage Therapeutics for $561 million as Cantor holds rating - Investing.com Canada
Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus - Yahoo Finance
Are Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market? - simplywall.st
SAGE to Be Acquired by Supernus Pharmaceuticals | SAGE Stock New - GuruFocus
Trading (SUPN) With Integrated Risk Controls - news.stocktradersdaily.com
Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal - whbl.com
Supernus Pharmaceuticals picks up embattled Sage Therapeutics - Mugglehead Magazine
Supernus Secures Sage With CVR-Supported Deal - insights.citeline.com
Supernus to Acquire Sage Therapeutics in $795M Deal - USA Herald
Saul Ewing-Led Supernus Inks Up To $795M Brain Health Deal - Law360
Deals of the day-Mergers and acquisitions - marketscreener.com
Supernus to acquire Sage Therapeutics for up to $795 million By Investing.com - Investing.com South Africa
Supernus enters depression drug market with up to $795 million Sage deal | Business Information & News | FE - Westlaw Today
Supernus To Acquire Sage: A Smart Move, Despite Both Pharmas' MDD Woes (NASDAQ:SUPN) - Seeking Alpha
Supernus Pharma's $795 Million Acquisition of Sage Therapeutics Boosts Shares - GuruFocus
Supernus’ $795 million bid sufficient for Sage - The Pharma Letter
Sage Therapeutics Stock Soars 36% After Sale to Supernus Pharmaceuticals. What We Know. - Barron's
Supernus Pharmaceuticals Inc Azioni (SUPN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):